Aardvark Therapeutics financials
$5.35+1.52%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$15.1M | -$22.5M | -$18.7M | -$17.7M | -$15.8M | -$10.5M |
| Net income | -$14.4M | -$21.6M | -$17.6M | -$16.3M | -$14.4M | -$9.3M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-0.66 | $-0.99 | $-0.80 | $-0.75 | $-0.66 | $-0.71 |
| EBITDA | -$15.1M | -$22.5M | -$18.7M | -$17.7M | -$15.8M | -$10.5M |
| Operating cash flow | -$17.6M | -$18.9M | -$16.8M | -$16.1M | -$9.8M | -$11.4M |
| Free cash flow | -$17.6M | -$18.9M | -$16.8M | -$16.1M | -$9.9M | -$11.4M |
| Diluted shares | 21.8M | 21.8M | 21.9M | 21.7M | 21.7M | 13.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $73.8M | $62.4M | $47.1M | $39.3M | $26.0M | $26.5M |
| Short-term investments | $21.0K | $28.8M | $63.0M | $87.1M | $115.8M | $124.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $81.5M | $98.6M | $117.2M | $133.2M | $147.5M | $157.0M |
| Total liabilities | $6.7M | $11.6M | $10.5M | $10.9M | $10.6M | $6.3M |
| Shareholders' equity | $74.8M | $87.0M | $106.6M | $122.4M | $136.9M | $150.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology